[1]亚太影像引导下肿瘤微创治疗协会,中国抗癌协会肿瘤微创治疗专业委员会,亚洲肿瘤消融学会（07）.肝细胞癌微创与多学科综合诊疗——2018广州共识[J].介入放射学杂志,2019,28(07):610-624.
　Asia-Pacific Association of Image-Guided Therapy of Oncology,Committee of Minimally Invasive Therapy in Oncology,Chinese Anti-Cancer Association,et al.Minimally-invasive and multidisciplinary comprehensive diagnosis and treatment for HCC： 2018 Guangzhou consensus [J].journal interventional radiology,2019,28(07):610-624.
点击复制

肝细胞癌微创与多学科综合诊疗——2018广州共识()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
28
期数:
2019年07期
页码:
610-624
栏目:
指南与共识
出版日期:
2019-07-25

文章信息/Info

Title:
Minimally-invasive and multidisciplinary comprehensive diagnosis and treatment for HCC： 2018 Guangzhou consensus
作者:
亚太影像引导下肿瘤微创治疗协会; 中国抗癌协会肿瘤微创治疗专业委员会; 亚洲肿瘤消融学会（2017）
Author(s):
Asia-Pacific Association of Image-Guided Therapy of Oncology;  Committee of Minimally Invasive Therapy in Oncology;  Chinese Anti-Cancer Association;  Asian Conference on Tumor Ablation 2017 WU Peihong;  LI Wang and CHEN Qifeng
Department of Medical Imaging and Minimally-Invasive Intervention， Cancer Prevention and Treatment Center， Sun Yat-sen University， Guangzhou， Guangdong Province 510060， China
关键词:
【关键词】 肝细胞癌; 微创治疗; 多学科综合治疗; 共识
文献标志码:
A
摘要:
【摘要】 中国绝大多数肝癌是乙型病毒性肝炎和肝硬化长期发展的结果，具有富血供、多中心起源特点，早期即可侵犯门静脉小分支并发生肝内转移。因此，肝癌发生之初即是一种局部器官和全身性疾病。为此，临床上需要采用包括局部治疗[手术切除、射频消融（RFA）、微波消融（MWA）、化学消融、冷冻消融等]、器官水平治疗[经导管动脉灌注化疗（TAIC）、TACE]和系统治疗（免疫治疗、抗病毒治疗、分子靶向治疗）在内的综合治疗方案。本共识阐述肝细胞癌微创与多学科综合诊断和治疗方法，凸显八大亮点：①肝动脉造影、肝动脉造影CT（CTHA）、动脉-门静脉造影CT（CTAP）、碘化油CT（Lp-CT）、TACE-CT有助于发现子灶，精确分期；②TACE/消融作为早期肝癌首选治疗；③浸润型肝癌作为独立分型；④微创综合治疗转移淋巴结；⑤M（转移）分期细化用于指导个体化治疗和判断预后；⑥肝癌伴肝功能严重失代偿是肝移植候选标准；⑦提倡生物免疫、中医中药、抗病毒及社会心理治疗贯穿各期治疗方案；⑧建议开展早、中期肝癌微创介入治疗与外科手术多中心随机对照试验研究。

参考文献/References:

[1]Torre LA， Bray F， Siegel RL， et al. Global cancer statistics， 2012[J]. CA Cancer J Clin， 2015， 65： 87-108.
[2]Chen W， Zheng R， Baade PD， et al. Cancer statistics in China， 2015[J]. CA Cancer J Clin， 2016， 66： 115-132.
[3]Tanaka M， Katayama F， Kato H， et al. Hepatitis B and C virus infection and hepatocellular carcinoma in China： a review of epidemiology and control measures[J]. J Epidemiol， 2011， 21： 401-416.
[4]Cohen GS， Black M. Multidisciplinary management of hepatocellular carcinoma： a model for therapy[J]. J Multidiscip Healthc， 2013， 6： 189-195.
[5]董安楠，李 旺，董 军，等．中国肝细胞癌的微创与多学科综合诊疗策略[J]．中华医学杂志，2015，95：1702-1706．
[6]Zhang BH， Yang BH， Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma[J]. J Cancer Res Clin Oncol， 2004， 130： 417-422.
[7]Eleftheriou N， Heathcote J， Thomas HC， et al. Serum alpha-fetoprotein levels in patients with acute and chronic liver disease.Relation to hepatocellular regeneration and development of primary liver cell carcinoma[J]. J Clin Pathol， 1977， 30： 704-708.
[8]Durazo FA， Blatt LM， Corey WG， et al. Des-gamma-carboxyprothrombin， alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis， cirrhosis and hepatocellular carcinoma[J]. J Gastroenterol Hepatol， 2008， 23： 1541-1548.
[9]Xu RH， Wei W， Krawczyk M， et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma[J]. Nat Mater， 2017， 16： 1155.
[10]Chen BB， Murakami T， Shih TT， et al. Novel imaging diagnosis for hepatocellular carcinoma： consensus from the 5th Asia-Pacific primary liver cancer expert meeting （Apple 2014）[J]. Liver Cancer， 2015， 4： 215-227.
[11]Merkle EM， Zech CJ， Bartolozzi C， et al. Consensus report from the 7th international forum for liver magnetic resonance imaging[J]. Eur Radiol， 2016， 26： 674-682.
[12]Forner A， Vilana R， Ayuso C， et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis： Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma[J]. Hepatology， 2008， 47： 97-104.
[13]Omata M， Lesmana LA， Tateishi R， et al. Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma[J]. Hepatol Int， 2010， 4： 439-474.
[14]Kneuertz PJ， Demirjian A， Firoozmand A， et al. Diffuse infiltrative hepatocellular carcinoma： assessment of presentation， treatment， and outcomes[J]. Ann Surg Oncol， 2012， 19： 2897-2907.
[15]Demirjian A， Peng P， Geschwind JF， et al. Infiltrating hepatocellular carcinoma： seeing the tree through the forest[J]. J Gastrointest Surg， 2011， 15： 2089-2097.
[16]Yu MH， Kim JH， Yoon JH， et al. Small （<= 1-cm） hepatocellular carcinoma： diagnostic performance and imaging features at gadoxetic acid-enhanced Mr imaging[J]. Radiology， 2014， 271： 748-760.
[17]Makita O， Yamashita Y， Arakawa A， et al. Diagnostic accuracy of helical CT arterial portography and CT hepatic arteriography for hypervascular hepatocellular carcinoma in chronic liver damage. An ROC analysis[J]. Acta radiol， 2000， 41： 464-469.
[18]Ohki T， Tateishi R， Akahane M， et al. Characteristics of hepatocellular carcinoma nodules newly detected by computed tomography during arteriography and arterial portography： preliminary report of a randomized controlled trial[J]. Hepatol Int， 2012， 6： 639-645.
[19]Ohki T， Tateishi R， Akahane M， et al. CT with hepatic arterioportography as a pretreatment examination for hepatocellular carcinoma patients： a randomized controlled trial[J]. Am J Gastroenterol， 2013， 108： 1305-1313.
[20]Kitao A， Zen Y， Matsui O， et al. Hepatocarcinogenesis： multistep changes of drainage vessels at ct during arterial portography and hepatic arteriography-radiologic-pathologic correlation[J]. Radiology， 2009， 252： 605-614.
[21]Nishie A， Tajima T， Asayama Y， et al. Radiological assessment of hepatic vein invasion by hepatocellular carcinoma using combined computed tomography hepatic arteriography and computed tomography arterial portography[J]. Jpn J Radiol， 2010， 28： 414-422.
[22]Rizvi S， Camci C， Yong Y， et al. Is post-Lipiodol CT better than i.v. contrast CT scan for early detection of HCC? A single liver transplant center experience[J]. Transplant Proc，2006 ，38：2993-2995.
[23]Zheng XH， Guan YS， Zhou XP， et al. Detection of hypervascular hepatocellular carcinoma： Comparison of multi-detector CT with digital subtraction angiography and Lipiodol CT[J]. World J Gastroenterol， 2005， 11： 200-203.
[24]Malagari K， Koskinas J， Brountzos E， et al. CT portography and post-lipiodol CT in the preinterventional work-up of primary and secondary liver tumors. A single center experience [J]. Hepatogastroenterology， 1999， 46： 2901-2908.
[25]Bizollon T， Rode A， Bancel B， et al. Diagnostic value and tolerance of Lipiodol-computed tomography for the detection of small hepatocellular carcinoma： correlation with pathologic examination of explanted livers[J]. J Hepatol， 1998， 28： 491-496.
[26]Chung YH. A strategy for early detection of recurrent hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization[J]. Intervirology， 2005， 48： 46-51.
[27]Bartolozzi C， Lencioni R， Caramella D， et al. Small hepatocellular carcinoma. Detection with US， CT， MR imaging， DSA， and Lipiodol-CT[J]. Acta Radiol，1996，37：69-74.
[28] 吴沛宏，张福君，吴志荣等.肝癌微创治疗与多学科综合治疗[M].北京：军事医学科学出版社，2003.9-9.
[29]Caturelli E， de Sio I. Biopsy diagnosis of hepatocellular carcinoma[J]. Hepatology， 2008， 47： 2145
[30]Qi X， Zhao Y， Li H， et al. Management of hepatocellular carcinoma： An overview of major findings from meta-analyses[J]. Oncotarget， 2016， 7： 34703-34751.
[31]Majumdar A， Roccarina D， Thorburn D， et al. Management of People with early-or very early-stage hepatocellular carcinoma：an attempted network meta-analysis[J].Cochrane Database Syst Rev，2017，3：CD011650.
[32]吕明德，匡 铭，梁力建，等．手术切除和经皮热消融治疗早期肝癌的随机对照临床研究[J]．中华医学杂志，2006，86：801-805．
[33]Duan C， Liu M， Zhang Z， et al. Radiofrequency ablation versus hepatic resection for the treatment of early-stage hepatocellular carcinoma meeting Milan criteria： a systematic review and meta-analysis[J]. World J Surg Oncol， 2013， 11： 190.
[34]Xu Y， Shen Q， Wang N， et al. Microwave ablation is as effective as radiofrequency ablation for very-early-stage hepatocellular carcinoma[J]. Chin J Cancer， 2017， 36： 14.
[35]Peng ZW， Lin XJ， Zhang YJ， et al. Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller： a retrospective comparative study[J]. Radiology， 2012， 262： 1022-1033.
[36]Weis S， Franke A， Mossner J， et al. Radiofrequency（thermal）ablation versus no intervention or other interventions for hepatocellular carcinoma[J].Cochrane Database Syst Rev，2013：CD003046.
[37]Mcwilliams JP， Yamamoto S， Raman SS， et al. Percutaneous ablation of hepatocellular carcinoma： current status[J]. J Vasc Interv Radiol ， 2010， 21 （8 Suppl）： S204-S213.
[38]Gervais DA， Arellano RS. Percutaneous tumor ablation for hepatocellular carcinoma[J]. Am J Roentgenol， 2011， 197： 789-794.
[39]Shen HP， Gong JP， Zuo GQ. Role of high-intensity focused ultrasound in treatment of hepatocellular carcinoma[J]. Am Surg， 2011， 77： 1496-1501.
[40]Chan AC， Cheung TT， Fan ST， et al. Survival analysis of high-intensity focused ultrasound therapy versus radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma[J]. Ann Surg， 2013， 257： 686-692.
[41]李传行，吴沛宏，范卫君，等．动脉栓塞化疗与高强度聚焦超声联合治疗大肝癌的临床疗效[J]．中华医学杂志，2009，89：754-757．
[42]Cannon R， Ellis S， Hayes D， et al. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures[J]. J Surg Oncol， 2013， 107： 544-549.
[43]Kingham TP， Karkar AM， D’angelica MI， et al. Ablation of perivascular hepatic malignant tumors with irreversible electroporation[J]. J Am Coll Surg， 2012， 215： 379-387.
[44]Lee YJ， Lu DS， Osuagwu F， et al. Irreversible electroporation in porcine liver： short- and long-term effect on the hepatic veins and adjacent tissue by CT with pathological correlation[J]. Invest Radiol， 2012， 47： 671-675.
[45]Lencioni R， de Baere T， Soulen MC， et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma： a systematic review of efficacy and safety data[J]. Hepatology， 2016， 64： 106-116.
[46]Shi M， Lu LG， Fang WQ， et al. Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma： single-blind， randomized trial[J]. J Natl Cancer Inst， 2013， 105： 59-68.
[47]Monier A， Guiu B， Duran R， et al. Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma： comparison between drug-eluting beads and lipiodol emulsion[J]. Eur Radiol， 2017， 27： 1431-1439.
[48]Lammer J， Malagari K， Vogl T， et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma： results of the PRECISION V study[J]. Cardiovasc Intervent Radiol， 2010， 33： 41-52.
[49]Martin R， Geller D， Espat J， et al. Safety and efficacy of trans arterial chemoembolization with Drug-Eluting beads in hepatocellular cancer： a systematic review[J]. Hepatogastroenterology， 2012， 59： 255-260.
[50]Gao S， Yang Z， Zheng Z， et al. Doxorubicin-Eluting bead versus conventional TACE for unresectable hepatocellular carcinoma： a meta-analysis[J]. Hepatogastroenterology， 2013， 60： 813-820.
[51]Pomfret EA， Washburn K， Wald C， et al. Report of a National conference on liver allocation in patients with hepatocellular carcinoma in the United States[J]. Liver Transpl， 2010， 16： 262-278.
[52]Mizuki A， Tatemichi M， Tsukada N， et al. Addition of transcatheter arterial chemoembolization decreased local recurrence but had no survival benefit to percutaneous ethanol injection therapy for patients with small hepatocellular carcinoma： a multicenter randomized control study[J]. Oncol Lett， 2010， 1： 855-859.
[53]Gu L， Liu H， Fan L， et al. Treatment outcomes of transcatheter arterial chemoembolization combined with local ablative therapy versus monotherapy in hepatocellular carcinoma： a meta-analysis[J]. J Cancer Res Clin Oncol， 2014， 140： 199-210.
[54]赵 明，王健鹏，吴沛宏，等．TACE与TACE联合RFA治疗中晚期原发性肝癌167例临床对比分析[J]．中华医学杂志，2010，90：2916-2921．
[55]陈奇峰，贾振宇，杨正强，等．肝动脉化疗栓塞联合微波消融与单独肝动脉化疗栓塞治疗大肝癌疗效meta分析[J]．介入放射学杂志，2017，26：225-231．
[56]Lau WY， Sangro B， Chen PJ， et al. Treatment for hepatocellular carcinoma with portal vein tumor thrombosis： the emerging role for radioembolization using yttrium-90[J]. Oncology， 2013， 84： 311-318.
[57]Park JW， Amarapurkar D， Chao Y， et al. Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma （EPOIHCC）[J]. Liver Int，2013，33：327-337.
[58]Chapiro J， Duran R， Geschwind JF. Combination of intra-arterial therapies and sorafenib：is there a clinical benefit?La Radiologia medica[J]. Radiol Med， 2014， 119： 476-482.
[59]Abdel-Rahman O， Elsayed ZA. Combination trans arterial chemoembolization （TACE） plus sorafenib for the management of unresectable hepatocellular carcinoma： a systematic review of the literature[J]. Dig Dis Sci， 2013， 58： 3389-3396.
[60]Fu QH， Zhang Q， Bai XL， et al. Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma： a systematic review and meta-analysis[J]. J Cancer Res Clin Oncol， 2014， 140： 1429-1440.
[61] Lencioni R， Llovet J M， Han G， et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC： The SPACE trial[J]. Journal of Hepatology， 2016， 64：1090-1098.
[62]Park MK， Gwak GY， Lim DH， et al. The efficacy of combined transarterial chemoembolization and 3-Dimensional conformal radiotherapy for hepatocellular carcinoma with main portal vein thrombosis[J]. Hepatogastroenterology， 2010， 57： 801-806.
[63]Tada F， Abe M， Hirooka M， et al. Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma[J]. Int J Oncol， 2012， 41： 1601-1609.
[64]Huang ZM， Li W， Li S， et al. Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients[J]. J Immunother， 2013， 36： 287-293.
[65]赵 明，吴沛宏，曾益新，等．经肝动脉栓塞化疗序贯联合射频消融和细胞因子诱导的杀伤细胞治疗肝细胞癌的随机研究[J]．中华医学杂志，2006，86：1823-1828．
[66]Takayama T， Sekine T， Makuuchi M， et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma： a randomised trial[J]. Lancet， 2000， 356：802-807.
[67]肝细胞癌抗病毒治疗专家组，吴孟超，叶胜龙，等．HBV/HCV相关性肝细胞癌抗病毒治疗专家共识[J]．肿瘤，2014，22：295-302．
[68]National Comprehensive Cancer Network. Hepatobiliary Cancers （Version4.2017）[EB/OL]. http：//www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf， 2017-10-9.
[69]European Association for the Study of the Liver. Electronic address eee，European Association for the Study of the L.EASL Clinical Practice Guidelines： management of hepatocellular carcinoma[J]. J Hepatol， 2018， 69： 182-236.
[70]Kokudo N， Hasegawa K， Akahane M， et al. Evidence-based clinical practice guidelines for hepatocellular carcinoma： The Japan Society of Hepatology 2013 update （3rd JSH-HCC Guidelines）[J]. Hepatol Res， 2015， 45.
[71]中华人民共和国卫生和计划生育委员会医政医管局．原发性肝癌诊疗规范（2017年版）[J]．中华消化外科杂志，2017，16：635-647．
[72]Liu PH， Hsu CY， Hsia CY， et al. Surgical resection versus radiofrequency ablation for single hepatocellular carcinoma[73] Chen MS， Li JQ， Zheng Y， et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma[J]. Ann surg，2006，243：321-328.
[74]Huang G， Chen X， Lau WY， et al. Quality of Life after surgical resection compared with radiofrequency ablation for small hepatocellular carcinomas[J].Br J Surg， 2014， 101： 1006-1015.
[75]Kang TW， Kim JM， Rhim H， et al. Small hepatocellular carcinoma： radiofrequency ablation versus nonanatomic Resection： propensity score analyses of long-term outcomes[J]. Radiology， 2015， 275： 908-919.
[76]Kutlu OC， Chan JA， Aloia TA， et al. Comparative effectiveness of first-line radiofrequency ablation versus surgical resection and transplantation for patients with early hepatocellular carcinoma[J]. Cancer， 2017， 123： 1817-1827.
[77]Cucchetti A， Piscaglia F， Cescon M， et al. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma[J]. J Hepatol， 2013， 59： 300-307.
[78]Wang X， Hu Y， Ren M， et al. Efficacy and Safety of Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization for Hepatocellular Carcinomas Compared with Radiofrequency Ablation Alone： A Time-to-Event Meta-Analysis[J]. Korean J Radiol， 2016 ，17：93-102.
[79]Peng ZW， Zhang YJ， Chen MS， et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma： a prospective randomized trial[J]. J Clin Oncol， 2012， 31： 426-432.
[80]Iezzi R， Pompili M， La Torre MF， et al. Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma[J]. Dig Liver Dis， 2015， 47： 242-248.
[81]Benvegnu L， Noventa F， Bernardinello E， et al. Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development[J]. Gut， 2001， 48： 110-115.
[82]Lyu N， Lin Y， Kong Y， et al. FOXAI： a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma[J]. Gut， 2018， 67： 395-396.
[83]Lyu N， Kong Y， Mu L， et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs.sorafenib for advanced hepatocellular carcinoma[J]. J Hepatol， 2018， 69： 60-69.
[84]杨柳青，秦叔逵，赵宁莉，等．FOLFOX 4方案治疗中晚期原发性肝癌的临床研究[J]．临床肿瘤学杂志，2013，18：108-113．
[85]Pan T， Xie QK， Lv N， et al. Percutaneous CT-guided radiofrequency ablation for lymph node oligometastases from hepatocellular carcinoma： a propensity score-matching analysis[J]. Radiology， 2017， 282： 259-270.
[86]Lee HS. Management of patients with hepatocellular carcinoma and extrahepatic metastasis[J]. Dig Dis， 2011， 29： 333-338.
[87]高 飞，顾仰葵，黄金华，等．CT引导下射频消融治疗肝癌腹膜后转移性淋巴结的临床价值[J]．中华医学杂志，2012，92：2897-2900．
[88]Gao F， Gu Y， Huang J， et al. Radiofrequency ablation of retroperitoneal metastatic lymph nodes from hepatocellular carcinoma[J]. Acad Radiol， 2012， 19： 1035-1040.
[89]高 飞，顾仰葵，黄金华，等．CT引导下125I近距离治疗肝癌腹膜后转移性淋巴结的临床价值[J]．中华医学杂志，2013，93：2155-2157．
[90]Shen LJ， Li W， Wang SY， et al. Image-based Multilevel Subdivision of M1 Category in TNM Staging System for Metastatic Nasopharyngeal Carcinoma[J]. Radiology， 2016， 280： 805-814.
[91]Khalil DN， Smith EL， Brentjens RJ， et al. The future of cancer treatment： immunomodulation， CARs and combination immunotherapy[J]. Nat Rev Clin Oncol， 2016， 13： 273-290.
[92]El-Khoueiry AB， Sangro B， Yau T， et al. Nivolumab in patients with advanced hepatocellular carcinoma （CheckMate 040）： an open-label， non-comparative， phase 1/2 dose escalation and expansion trial[J]. Lancet， 2017， 389： 2492-2502.
[93]Greten TF， Manns MP， Korangy F. Immunotherapy of hepatocellular carcinoma[J]. J Hepatol， 2006， 45： 868-878.
[94]高继良．肝复乐方剂治疗晚期原发性肝癌的前瞻性、随机对照临床研究[J]．中国中药杂志，2014，39：2367-2369．
[95]Yin J， Li N， Han Y， et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma： a two-stage longitudinal clinical study[J]. J Clin Oncol， 2013， 31： 3647-3655.
[96]Huang G， Lau WY， Wang ZG， et al. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma a randomized controlled trial[J]. Ann Surg， 2015， 261： 56-66.
[97]Xu XL， Liu XD， Liang M， et al. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma： systematic review of randomized controlled trials with meta-analysis and trial sequential analysis[J]. Radiology， 2018， 287： 461-472.

相似文献/References:

[1]姚雪松,李 槐.不可手术切除的肝细胞癌的疗效评价标准——改良ＲＥＣＩＳＴ标准更可靠[J].介入放射学杂志,2012,(03):177.
　. Ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ ｃｒｉｔｅｒｉｏｎ ｏｆ ｉｎｏｐｅｒａｂｌｅ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ｍｏｄｉｆｉｅｄ ＲＥＣＩＳＴ ａｓ ａ ｍｏｒｅ ｒｅｌｉａｂｌｅ ｓｔａｎｄａｒｄ[J].journal interventional radiology,2012,(07):177.
[2]罗荣光,顾仰葵,高飞,等.单针灌注电极射频消融治疗肝脏肿瘤疗效分析[J].介入放射学杂志,2010,(08):617.
　LUO Rongguang,GU Yangkui,GAO Fei,et al.Radiofrequency ablation of liver tumors by using monopolar perfusion electrode：an analysis of therapeutic results[J].journal interventional radiology,2010,(07):617.
[3]梁茂全,苏洪英. 肝癌化疗栓塞前后甲胎蛋白变化模式的临床意义[J].介入放射学杂志,2012,(04):333.
　.Ｔｈｅ ｔｒａｎｓｆｏｒｍａｔｉｏｎ ｐａｔｔｅｒｎ ｏｆ ｓｅｒｕｍ аｆｅｔｏｐｒｏｔｅｉｎ ａｆｔｅｒ ｔｒａｎｓｃａｔｈｅｔｅｒ ａｒｔｅｒｉａｌ ｃｈｅｍｏｅｍｂｏｌｉｚａｔｉｏｎ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａ： ｉｔｓ ｃｌｉｎｉｃａｌ ｓｉｇｎｉｆｉｃａｎｃｅ [J].journal interventional radiology,2012,(07):333.
[4]孙 磊,施海彬,刘 圣,等.肝细胞癌肝动脉门静脉分流形成的相关因素分析[J].介入放射学杂志,2012,(03):206.
　,,et al.Ｔｈｅ ｆａｃｔｏｒｓ ｒｅｌａｔｅｄ ｔｏ ｔｈｅ ｆｏｒｍａｔｉｏｎ ｏｆ ａｒｔｅｒｉｏｐｏｒｔａｌ ｓｈｕｎｔｉｎｇ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ [J].journal interventional radiology,2012,(07):206.
[5]沈海洋,刘瑞宝,刘 岩,等. 肝右叶前、后段原发性肝癌TACE后VEGF及CD34的表达水平 ；[J].介入放射学杂志,2012,(06):469.
　SHEN Hai- yang,LIU Rui- bao,LIU Yan,et al. The expression levels of vascular endothelial growth factor and CD34 in residual cancerous tissues of primary hepatocellular carcinoma located at anterior and posterior segments of right lobe liver after TACE[J].journal interventional radiology,2012,(07):469.
[6]李晓峰,钱国军,张 磊,等. 微波高功率条件下消融原发性肝癌的初步研究[J].介入放射学杂志,2011,(12):974.
　LI Xiao-feng,QIAN Guo-jun,ZHANG Lei,et al.Microwave ablation with high output power for the treatment of hepatocellular carcinoma: a preliminary study[J].journal interventional radiology,2011,(07):974.
[7]彭辽河,胡晓燕,李 杰,等. 18F-FDG PET/CT显像在肝细胞癌TACE术后残留或复发病灶检出中的应用价值[J].介入放射学杂志,2012,(08):636.
　PENG Liao- he,HU Xiao- yan,LI Jie,et al. Clinical application of 18F- FDG PET/CT imaging in detecting residual lesions or recurrence foci of hepatocellular carcinoma after TACE treatment[J].journal interventional radiology,2012,(07):636.
[8]陆小华,朱小庆,茅国新.肝细胞癌相关单核苷酸多态性的研究进展[J].介入放射学杂志,2013,(06):520.
　LU Xiao? hua,ZHU Xiao? qing,MAO Guo? xin.. Hepatocellular carcinoma?蛳 related single nucleotide polymorphisms： recent advances in research[J].journal interventional radiology,2013,(07):520.
[9]姚雪松,闫 东,曾辉英,等.TACE联合索拉非尼治疗不能手术切除肝细胞癌介入治疗间隔时间的分析[J].介入放射学杂志,2014,(09):769.
　YAO Xue song,YAN Dong,ZENG Hui ying,et al.TACE combined with sorafenib for inoperable hepatocellular carcinoma： analysis of treatment interval[J].journal interventional radiology,2014,(07):769.
[10]姚雪松,闫 东,曾辉英,等. TACE联合索拉非尼治疗不能手术切除肝细胞肝癌50例[J].介入放射学杂志,2013,(05):381.
　YAO Xue? song,YAN Dong,ZENG Hui? ying,et al. Ttransarterial chemoembolization combined with sorafenib for inoperable hepatocellular carcinoma： a clinical analysis of 50 cases[J].journal interventional radiology,2013,(07):381.

备注/Memo

备注/Memo:
（收稿日期：2019-01-23）
（本文编辑：边佶）
更新日期/Last Update: 2019-07-15